ClinicalTrials.gg
CompletedNCT05114590Soli-CGMUpdated Sep 9, 2025Results posted

Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus

A Phase 4 interventional study of Insulin glargine/Lixisenatide in Type 2 Diabetes Mellitus, sponsored by Sanofi. Completed at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-09.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
124
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.

Enrollment
114th of 175
124 · median 253
Started
2022
with 6 others
Phase 4
103 of 176
2 open now
Registered
163rd of 176
by date
Lead sponsor
82 of 176
Sanofi

Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 114th largest by enrollment of the 175 interventional ones that give a count, is one of 7 that started in 2022, is one of 103 in phase 4, and was the 163rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of the study was to demonstrate if iGlarLixi (Soliqua 100/33) would improve glycemic control (as measured by Time in Range) and glycemic variability in participants with very uncontrolled (HbA1c ≥ 9%) type 2 Diabetes Mellitus (T2DM) while on at least 2 oral antidiabetic drugs [OADs] with or without a glucagon-like peptide 1 receptor agonist [GLP1 RA]), as measured by continuous glucose monitoring (CGM).

The total study duration per participant was approximately 22 weeks. Three site visits, 3 site or home visits, and up to 13 phone contacts were scheduled.

  • A screening period of up to 2 weeks
  • A run-in period of up to 2 weeks, including the baseline period
  • A 16-week, open-label treatment period
  • A 2-week post-treatment safety follow-up period
03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with Type 2 Diabetes mellitus (T2DM) for at least 6 months before the baseline period
  • ≥9-13% during the run-in period
  • On at least 2 OADs with or without GLP-1 RA with stable doses (for both) for 3 months prior to the screening period
  • Willing and able to wear the CGM device continuously for 14 days to capture CGM measures at baseline until the next site visit and again towards the end of the treatment period
  • Willing and able to prick fingers a minimum of 2-4 times per week utilizing sterile lancets provided along with a manual blood glucose meter kit
  • Willing to discontinue the daily (oral or injectable) or weekly GLP-1 RA or DPP 4i prior to administration of iGlarLixi (Soliqua 100/33)
  • Willing and able to inject iGlarLixi (Soliqua 100/33) and increase dose as needed to achieve SMPG target
  • Non-pregnant, non-breastfeeding women utilizing a highly-effective method or of non-

Exclusion criteria

Exclusion Criteria:

  • Type1 Diabetes mellitus (T1DM) or any other types of diabetes, except T2DM
  • On meglitinides (eg, nateglinide, repaglinide)
  • (BMI) >40 kg/m² during the screening period
  • Any current or previous skin conditions, including (but not limited to) severe psoriasis, burns, eczema, scarring, excessive tattoos, that would inhibit the proper wearing of the CGM device
  • History of severe nausea and vomiting leading to subsequent discontinuation of GLP-1 RA
  • Known history or presence of pancreatitis or gastroparesis
  • Participants with an episode of severe hypoglycemia or with hypoglycemia unawareness (defined as the onset of neuroglycopenia before the appearance of autonomic warning symptoms [for example, blurred vision, difficulty speaking, feeling faint, difficulty thinking, and confusion] or as the failure to sense a significant fall in blood glucose below normal levels) diagnosed within the 6 months prior to the screening period
  • Participants with personal or immediate family history of medullary thyroid cancer (MTC) or genetic conditions that predisposed to MTC (eg, multiple endocrine neoplasia syndromes)
  • Significant current (within past 2 months) and/or expected use of medications known to affect glycemia (eg, ≥5 mg/day prednisone)
  • Use of substances known to interfere with CGM readings, such as aspirin-containing products (>650 mg/day of salicylic acid) or supplements containing vitamin C (>1000 mg/day of ascorbic acid) during the 14 days of CGM at either baseline or end of treatment period
  • Previous treatment with any insulin (except for short term treatment due to intercurrent illness, including gestational diabetes, at the discretion of the investigator)
  • Had used weight loss drugs (including over the counter and herbal medications) within 12 weeks before the screening visit

The above information was not intended to contain all considerations relevant to a potential participation in a clinical trial

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
124 participants (actual)

Study arms

  • Experimental
    iGlarLixi

    iGlarLixi (i.e., insulin glargine 100 Units/ml /lixisenatide 33 μg/mL) once daily for 16 weeks.

    Drug: Insulin glargine/Lixisenatide

Interventions

  • DrugInsulin glargine/Lixisenatide

    Drug pages: Insulin Glargine · Lixisenatide

    Solution for injection in a pre-filled pen by subcutaneous injection. Dose was individually titrated to achieve target fasting self-monitoring of plasma glucose (SMPG) of 80 to 100 milligrams per deciliter (mg/dL) (4.4 to 5.6 millimoles per liter \[mmol/L\]) while avoiding hypoglycemia.

    Also known as: iGlarLixi, Soliqua 100/33, AVE0010-1

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 16 in the Percentage of Time in Range [70 to 180 Milligram Per Deciliter (mg/dL)]

    The percentage of time spent in the glycemic target range of 70 to 180 mg/dL was calculated as 100 times the number of recorded measurements in the glycemic target range (70 to 180 mg/dL inclusive), divided by the total number of recorded measurements. Baseline is defined as the first 14 evaluable days of evaluable continuous glucose monitoring (CGM) data prior to first day of treatment. CGM compliance is defined as 1) at least 8 out of 14 days (not necessarily consecutive) have 100% of evaluable CGM data per 24-hour period (at least 8 days with 96 records minimum per day) OR 2) at least 9 out of 14 days (not necessarily consecutive) have ≥89% of evaluable CGM data per 24-hour period (at least 9 days with 85 records minimum per day) OR 3) at least 10 out of 14 days (not necessarily consecutive) have at least ≥80% of evaluable CGM data per 24 hour period (at least 10 days with 77 records minimum per day).

    Time frame: Baseline (Days -14 to -1) and Week 16

Secondary outcomes

  1. Percent Change From Baseline to Week 16 in Glucose Total Coefficient of Variation (CV)

    Glucose total CV was calculated by following: standard deviation glucose/mean glucose over 14 days x 100, and the percent change was reported. Baseline is defined as the first 14 evaluable days of evaluable CGM data prior to first day of treatment.

    Time frame: Baseline (Days -14 to -1) and Week 16

  2. Change From Baseline to Week 16 in Mean Daily Blood Glucose

    A global average was computed to determine the average of the mean daily blood glucose for the 14 days at baseline and Week 16. Baseline is defined as the first 14 evaluable days of evaluable CGM data prior to first day of treatment.

    Time frame: Baseline (Days -14 to -1) and Week 16

  3. Change From Baseline to Week 16 in the Maximum Postprandial Glucose Exposure in the 4 Hours Post-Breakfast Meal

    The analysis was focused on the 4-hour interval at both baseline and Week 16 from t=0 (the timepoint at which glucose measurement was taken immediately preceding liquid meal administration) throughout the subsequent 4 hours. For each participant, the overall maximum glucose value within the described 4-hour period was determined, and the difference between the maximum glucose value at baseline and Week 16 was reported. Baseline is defined as the first 14 evaluable days of evaluable CGM data prior to first day of treatment.

    Time frame: Baseline (Days -14 to -1) and Week 16

  4. Change From Baseline to Week 16 in Time Above Range (>180 mg/dL)

    The time spent above the glycemic target range was calculated as 100 times the total number of 15-minute increments of CGM data where a participant's blood glucose falls above normal range (\>180 mg/dL) at baseline, divided by the total number of 15-minute increments read (i.e., up to 1344 15-minute increments) at Week 16. This was calculated for baseline and Week 16 and the change was reported. Baseline is defined as the first 14 evaluable days of evaluable CGM data prior to first day of treatment.

    Time frame: Baseline (Days -14 to -1) and Week 16

  5. Percentage of Participants Who Achieved Coefficient of Variation <36%

    Percentage of participants achieving CV \<36% was calculated as sum of the number of participants with CV \<36% divided by the total number of participants. The endpoint was calculated using all CGM glucose readings available throughout each day for 2 weeks (Week 14-16).

    Time frame: Week 16

  6. Change From Baseline to Week 16 in Time in Range Per Time Blocks

    Time spent in the glycemic target range (70 to 180 mg/dL) was calculated as 100 times the number of recorded measurements in the glycemic target range (70 to 180 mg/dL inclusive), divided by the total number of recorded measurements per time block and comparing the corresponding time blocks from Week 16 to baseline. The time blocks are 12 am to 6 am, 6 am to 12 pm, 12 pm to 6 pm, 6 pm to 12 am, and 6 am to 12 am. Baseline is defined as the first 14 evaluable days of evaluable CGM data prior to first day of treatment.

    Time frame: Baseline (Days -14 to -1) and Week 16

  7. Percentage of Participants Who Achieved Glucose Management Indicator (GMI) <7% and <9%

    The GMI was calculated as 3.31 + 0.02392 x (mean glucose in mg/dL from CGM data). The GMI was calculated by determining the number of participants who achieved \<7% and \<9% at Week 16.

    Time frame: Week 16

  8. Change From Baseline to Week 16 in the 4-Hour Postprandial Glucose Area Under the Concentration Time Curve From 0 to 4 Hours

    Blood samples were collected to measure the glucose values up to 4-hour after the breakfast meal. The analysis was based on a liquid meal at both baseline and Week 16 (a liquid meal administered in a fasted state and blood glucose is measured at specific time points up to 4 hours). Baseline is defined as the time period prior to administration of study drug.

    Time frame: Baseline (Days -14 to -1) and Week 16

  9. Change From Baseline to Week 16 in Time to Reach Maximum Postprandial Glucose Concentration

    Blood samples were collected at specific intervals over a 4 hour period to measure blood glucose values following ingestion of a liquid meal and the process is repeated after 16 weeks of study drug administration following another liquid meal administration and blood glucose values measured at specific time points over 4 hours. The difference in the time to reach the maximal blood glucose value was then calculated between these two timepoints.

    Time frame: Baseline (Days -14 to -1) and Week 16

  10. Percentage of Participants Who Spent <15 Minutes/Day at a Glucose Level <54 mg/dL

    Blood glucose level was determined based upon CGM data. Percentage of participants with glucose level \<54 mg/dL for less than 15 minutes per day are reported.

    Time frame: Week 16

  11. Change From Baseline to Week 16 in Overall Score of Diabetes Medication Treatment Satisfaction Scores Using the Diabetes Medication Satisfaction Tool (DM-SAT) Questionnaire

    The changes in diabetes medication treatment-related impact and satisfaction was measured by the DM-SAT. The DM-SAT is a 16-item measure with 4 domains/subscales assessing lifestyle (5 items), medical control (3 items), convenience (5 items) and well being (3 items). Each item is measured on a scale from 0-10, where 0= not at all satisfied, 1 to 3= not too satisfied, 4 to 6 = somewhat satisfied, 7-9= very satisfied and 10= extremely satisfied. The overall score was calculated as the sum of the 16 questions with a score that ranges from 0 to 160. A higher score indicates a positive result. Baseline is defined as the first 14 evaluable days of evaluable CGM data prior to first day of administration.

    Time frame: Baseline (Days -14 to -1) and Week 16

  12. Number of Participants With Confirmed Hypoglycemia Measured by Blood Glucose Levels

    Hypoglycemia event is defined as any event recorded in hypoglycemic event information library electronic case report form page that has "Yes" as the response to the question "Were any hypoglycemic events experienced". American Diabetes Association (ADA) Level 1 hypoglycemia is defined as measurable glucose concentration \<70 mg/dL \[3.9 millimoles per liter (mmol/L)\] but \>=54 mg/dL (3.0 mmol/L). ADA Level 2 hypoglycemia is defined as measurable glucose concentration \<54 mg/dL (3.0 mmol/L) that needed immediate action. ADA Level 3 hypoglycemia is defined as severe event characterized by altered mental and/or physical functioning that required assistance from another person for recovery of adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest. Participants might have experienced both Level 1 and 2 hypoglycemia events.

    Time frame: From the first administration of the study drug (Day 1) up to 3 days after last administration of the study drug (maximum exposure duration: up to 16 weeks)

  13. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events

    An AE is any untoward medical occurrence in a participant or clinical study participant, whether or not considered related to the study drug. An SAE is defined as any AE that, at any dose, meets one of the following criteria: results in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent or significant disability/incapacity or congenital anomaly/birth defect. TEAEs is defined as AEs that developed, worsened, or became serious during the treatment-emergent period, defined as the time from the first administration of the study drug (Day 1) to the last administration of the study drug + 3 days.

    Time frame: From the first administration of the study drug (Day 1) up to 3 days after last administration of the study drug (maximum exposure duration: up to 16 weeks)

07

Results

Posted May 24, 2024

Participant flow

The study was conducted at 17 centers in the United States. A total of 244 participants were screened between 27 January 2022 and 03 December 2022, of which 120 were screen failures. Screen failures were mainly due to not meeting glycated hemoglobin inclusion criteria.

Participant flow — Overall Study
MilestoneiGlarLixi
Started124
Completed the 16-week study treatment period111
Completed110
Not completed14
Withdrew: Adverse event1
Withdrew: Investigator decision1
Withdrew: Lost to follow-up5
Withdrew: Withdrawal by subject5
Withdrew: Other2

Outcome measures

PrimaryChange From Baseline to Week 16 in the Percentage of Time in Range [70 to 180 Milligram Per Deciliter (mg/dL)]

The percentage of time spent in the glycemic target range of 70 to 180 mg/dL was calculated as 100 times the number of recorded measurements in the glycemic target range (70 to 180 mg/dL inclusive), divided by the total number of recorded measurements. Baseline is defined as the first 14 evaluable days of evaluable continuous glucose monitoring (CGM) data prior to first day of treatment. CGM compliance is defined as 1) at least 8 out of 14 days (not necessarily consecutive) have 100% of evaluable CGM data per 24-hour period (at least 8 days with 96 records minimum per day) OR 2) at least 9 out of 14 days (not necessarily consecutive) have ≥89% of evaluable CGM data per 24-hour period (at least 9 days with 85 records minimum per day) OR 3) at least 10 out of 14 days (not necessarily consecutive) have at least ≥80% of evaluable CGM data per 24 hour period (at least 10 days with 77 records minimum per day).

Time frame:
Baseline (Days -14 to -1) and Week 16
Reported as:
Mean · percentage of time
Change From Baseline to Week 16 in the Percentage of Time in Range [70 to 180 Milligram Per Deciliter (mg/dL)]
percentage of timeiGlarLixi
Change From Baseline to Week 16 in the Percentage of Time in Range [70 to 180 Milligram Per Deciliter (mg/dL)]26.22 (20.5 to 31.9)
SecondaryPercent Change From Baseline to Week 16 in Glucose Total Coefficient of Variation (CV)

Glucose total CV was calculated by following: standard deviation glucose/mean glucose over 14 days x 100, and the percent change was reported. Baseline is defined as the first 14 evaluable days of evaluable CGM data prior to first day of treatment.

Time frame:
Baseline (Days -14 to -1) and Week 16
Reported as:
Mean · percent change
Percent Change From Baseline to Week 16 in Glucose Total Coefficient of Variation (CV)
percent changeiGlarLixi
Percent Change From Baseline to Week 16 in Glucose Total Coefficient of Variation (CV)5.0 (3.8 to 6.1)
SecondaryChange From Baseline to Week 16 in Mean Daily Blood Glucose

A global average was computed to determine the average of the mean daily blood glucose for the 14 days at baseline and Week 16. Baseline is defined as the first 14 evaluable days of evaluable CGM data prior to first day of treatment.

Time frame:
Baseline (Days -14 to -1) and Week 16
Reported as:
Mean · mg/dL
Change From Baseline to Week 16 in Mean Daily Blood Glucose
mg/dLiGlarLixi
Change From Baseline to Week 16 in Mean Daily Blood Glucose-52.48 (-64.6 to -40.3)
SecondaryChange From Baseline to Week 16 in the Maximum Postprandial Glucose Exposure in the 4 Hours Post-Breakfast Meal

The analysis was focused on the 4-hour interval at both baseline and Week 16 from t=0 (the timepoint at which glucose measurement was taken immediately preceding liquid meal administration) throughout the subsequent 4 hours. For each participant, the overall maximum glucose value within the described 4-hour period was determined, and the difference between the maximum glucose value at baseline and Week 16 was reported. Baseline is defined as the first 14 evaluable days of evaluable CGM data prior to first day of treatment.

Time frame:
Baseline (Days -14 to -1) and Week 16
Reported as:
Mean · mg/dL
Change From Baseline to Week 16 in the Maximum Postprandial Glucose Exposure in the 4 Hours Post-Breakfast Meal
mg/dLiGlarLixi
Change From Baseline to Week 16 in the Maximum Postprandial Glucose Exposure in the 4 Hours Post-Breakfast Meal-73.66 (-90.9 to -56.4)
SecondaryChange From Baseline to Week 16 in Time Above Range (>180 mg/dL)

The time spent above the glycemic target range was calculated as 100 times the total number of 15-minute increments of CGM data where a participant's blood glucose falls above normal range (\>180 mg/dL) at baseline, divided by the total number of 15-minute increments read (i.e., up to 1344 15-minute increments) at Week 16. This was calculated for baseline and Week 16 and the change was reported. Baseline is defined as the first 14 evaluable days of evaluable CGM data prior to first day of treatment.

Time frame:
Baseline (Days -14 to -1) and Week 16
Reported as:
Mean · percentage of time
Change From Baseline to Week 16 in Time Above Range (>180 mg/dL)
percentage of timeiGlarLixi
Change From Baseline to Week 16 in Time Above Range (>180 mg/dL)-28.67 (-34.6 to -22.7)
SecondaryPercentage of Participants Who Achieved Coefficient of Variation <36%

Percentage of participants achieving CV \<36% was calculated as sum of the number of participants with CV \<36% divided by the total number of participants. The endpoint was calculated using all CGM glucose readings available throughout each day for 2 weeks (Week 14-16).

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Coefficient of Variation <36%
percentage of participantsiGlarLixi
Percentage of Participants Who Achieved Coefficient of Variation <36%76.0 (66.4 to 84.0)
SecondaryChange From Baseline to Week 16 in Time in Range Per Time Blocks

Time spent in the glycemic target range (70 to 180 mg/dL) was calculated as 100 times the number of recorded measurements in the glycemic target range (70 to 180 mg/dL inclusive), divided by the total number of recorded measurements per time block and comparing the corresponding time blocks from Week 16 to baseline. The time blocks are 12 am to 6 am, 6 am to 12 pm, 12 pm to 6 pm, 6 pm to 12 am, and 6 am to 12 am. Baseline is defined as the first 14 evaluable days of evaluable CGM data prior to first day of treatment.

Time frame:
Baseline (Days -14 to -1) and Week 16
Reported as:
Mean · percentage of time
Change From Baseline to Week 16 in Time in Range Per Time Blocks
percentage of timeiGlarLixi
12 am to 6 am27.89 (21.3 to 34.5)
6 am to 12 pm33.73 (27.0 to 40.5)
12 pm to 6 pm31.05 (24.5 to 37.6)
6 pm to 12 am25.87 (19.8 to 31.9)
6 am to 12 am30.21 (24.1 to 36.3)
SecondaryPercentage of Participants Who Achieved Glucose Management Indicator (GMI) <7% and <9%

The GMI was calculated as 3.31 + 0.02392 x (mean glucose in mg/dL from CGM data). The GMI was calculated by determining the number of participants who achieved \<7% and \<9% at Week 16.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Glucose Management Indicator (GMI) <7% and <9%
percentage of participantsiGlarLixi
GMI <7%43.0 (33.1 to 53.3)
GMI <9%85.0 (76.5 to 91.4)
SecondaryChange From Baseline to Week 16 in the 4-Hour Postprandial Glucose Area Under the Concentration Time Curve From 0 to 4 Hours

Blood samples were collected to measure the glucose values up to 4-hour after the breakfast meal. The analysis was based on a liquid meal at both baseline and Week 16 (a liquid meal administered in a fasted state and blood glucose is measured at specific time points up to 4 hours). Baseline is defined as the time period prior to administration of study drug.

Time frame:
Baseline (Days -14 to -1) and Week 16
Reported as:
Mean · mg/dL*hour
Change From Baseline to Week 16 in the 4-Hour Postprandial Glucose Area Under the Concentration Time Curve From 0 to 4 Hours
mg/dL*houriGlarLixi
Change From Baseline to Week 16 in the 4-Hour Postprandial Glucose Area Under the Concentration Time Curve From 0 to 4 Hours-325.93 (-390.6 to -261.2)
SecondaryChange From Baseline to Week 16 in Time to Reach Maximum Postprandial Glucose Concentration

Blood samples were collected at specific intervals over a 4 hour period to measure blood glucose values following ingestion of a liquid meal and the process is repeated after 16 weeks of study drug administration following another liquid meal administration and blood glucose values measured at specific time points over 4 hours. The difference in the time to reach the maximal blood glucose value was then calculated between these two timepoints.

Time frame:
Baseline (Days -14 to -1) and Week 16
Reported as:
Mean · hour
Change From Baseline to Week 16 in Time to Reach Maximum Postprandial Glucose Concentration
houriGlarLixi
Change From Baseline to Week 16 in Time to Reach Maximum Postprandial Glucose Concentration-0.24 (-0.5 to 0.0)
SecondaryPercentage of Participants Who Spent <15 Minutes/Day at a Glucose Level <54 mg/dL

Blood glucose level was determined based upon CGM data. Percentage of participants with glucose level \<54 mg/dL for less than 15 minutes per day are reported.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Spent <15 Minutes/Day at a Glucose Level <54 mg/dL
percentage of participantsiGlarLixi
Percentage of Participants Who Spent <15 Minutes/Day at a Glucose Level <54 mg/dL63.0 (52.8 to 72.4)
SecondaryChange From Baseline to Week 16 in Overall Score of Diabetes Medication Treatment Satisfaction Scores Using the Diabetes Medication Satisfaction Tool (DM-SAT) Questionnaire

The changes in diabetes medication treatment-related impact and satisfaction was measured by the DM-SAT. The DM-SAT is a 16-item measure with 4 domains/subscales assessing lifestyle (5 items), medical control (3 items), convenience (5 items) and well being (3 items). Each item is measured on a scale from 0-10, where 0= not at all satisfied, 1 to 3= not too satisfied, 4 to 6 = somewhat satisfied, 7-9= very satisfied and 10= extremely satisfied. The overall score was calculated as the sum of the 16 questions with a score that ranges from 0 to 160. A higher score indicates a positive result. Baseline is defined as the first 14 evaluable days of evaluable CGM data prior to first day of administration.

Time frame:
Baseline (Days -14 to -1) and Week 16
Reported as:
Mean · units on a scale
Change From Baseline to Week 16 in Overall Score of Diabetes Medication Treatment Satisfaction Scores Using the Diabetes Medication Satisfaction Tool (DM-SAT) Questionnaire
units on a scaleiGlarLixi
Change From Baseline to Week 16 in Overall Score of Diabetes Medication Treatment Satisfaction Scores Using the Diabetes Medication Satisfaction Tool (DM-SAT) Questionnaire0.18 (0.14 to 0.22)
SecondaryNumber of Participants With Confirmed Hypoglycemia Measured by Blood Glucose Levels

Hypoglycemia event is defined as any event recorded in hypoglycemic event information library electronic case report form page that has "Yes" as the response to the question "Were any hypoglycemic events experienced". American Diabetes Association (ADA) Level 1 hypoglycemia is defined as measurable glucose concentration \<70 mg/dL \[3.9 millimoles per liter (mmol/L)\] but \>=54 mg/dL (3.0 mmol/L). ADA Level 2 hypoglycemia is defined as measurable glucose concentration \<54 mg/dL (3.0 mmol/L) that needed immediate action. ADA Level 3 hypoglycemia is defined as severe event characterized by altered mental and/or physical functioning that required assistance from another person for recovery of adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest. Participants might have experienced both Level 1 and 2 hypoglycemia events.

Time frame:
From the first administration of the study drug (Day 1) up to 3 days after last administration of the study drug (maximum exposure duration: up to 16 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Confirmed Hypoglycemia Measured by Blood Glucose Levels
ParticipantsiGlarLixi
Any Hypoglycemia events35
Hypoglycemia events confirmed by ADA criteria29
ADA Level 1 hypoglycemia26
ADA Level 2 hypoglycemia11
ADA Level 3 hypoglycemia0
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events

An AE is any untoward medical occurrence in a participant or clinical study participant, whether or not considered related to the study drug. An SAE is defined as any AE that, at any dose, meets one of the following criteria: results in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent or significant disability/incapacity or congenital anomaly/birth defect. TEAEs is defined as AEs that developed, worsened, or became serious during the treatment-emergent period, defined as the time from the first administration of the study drug (Day 1) to the last administration of the study drug + 3 days.

Time frame:
From the first administration of the study drug (Day 1) up to 3 days after last administration of the study drug (maximum exposure duration: up to 16 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events
ParticipantsiGlarLixi
Any TEAE47
Any treatment-emergent SAE1

Adverse events

Collected over TEAEs data was collected from the first administration of the study drug (Day 1) up to 3 days after last administration of the study drug (maximum exposure duration: up to 16 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
iGlarLixi0/123 (0%)1/123 (0.8%)14/123 (11.4%)
Most frequent serious events
Most frequent serious events
EventiGlarLixi
HypoglycaemiaMetabolism and nutrition disorders1/123
Most frequent other events
Most frequent other events
EventiGlarLixi
Upper Respiratory Tract InfectionInfections and infestations7/123
HypoglycaemiaMetabolism and nutrition disorders7/123

Baseline characteristics

Enrolled set included all eligible participants who were dispensed iGlarLixi and signed the informed consent form.

Age, Continuous
Age, Continuous(years)iGlarLixi
Mean55.6 ± 11.08
Sex: Female, Male
Sex: Female, Male(Participants)iGlarLixi
Female51
Male73
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)iGlarLixi
Asian6
Black21
White89
Multiple1
Not Reported2
Other5
08

Study locations

18 sites
  • Clearview Medical Research LLC-Site Number:8400003
    Canyon Country, California 91351-4138, United States
  • National Research Institute - ClinEdge - PPDS-Site Number:8400004
    Huntington Park, California 90255-2959, United States
  • National Research Institute - ClinEdge - PPDS-Site Number:8400009
    Huntington Park, California 90255-2959, United States
  • Torrance Clinical Research Institute-Site Number:8400008
    Lomita, California 90717-2101, United States
  • Downtown LA Research Center Inc - ClinEdge - PPDS-Site Number:8400001
    Los Angeles, California 90017-5649, United States
  • University Clinical Investigators Inc-Site Number:8400020
    Tustin, California 92780, United States
  • San Fernando Valley Health Institute - ClinEdge - PPDS-Site Number:8400012
    West Hills, California 91304-3837, United States
  • Premier Research Associate-Miami-Site Number:8400002
    Miami, Florida 33165-7043, United States
  • Floridian Research Institute-Site Number:8400013
    Miami, Florida 33179-2537, United States
  • Palm Research Center, Inc.-Site Number:8400005
    Las Vegas, Nevada 89128-0463, United States
  • Hassman Research Institute - HRI - Berlin - CenExel - PPDS-Site Number:8400007
    Berlin, New Jersey 08009, United States
  • Mid Hudson Medical Research PLLC-Site Number:8400014
    New Windsor, New York 12553-7754, United States
  • Endocrinology Associates Inc-Site Number:8400011
    Columbus, Ohio 43201-3209, United States
  • University of Tennessee Health Science Center-Site Number:8400017
    Memphis, Tennessee 38163, United States
  • University of Texas Southwestern Medical Center-Site Number:8400018
    Dallas, Texas 75390, United States
  • Flourish Research - San Antonio - PPDS-Site Number:8400006
    San Antonio, Texas 78229-3539, United States
  • Northeast Clinical Research of San Antonio LLC-Site Number:8400019
    Schertz, Texas 78154, United States
  • Consano Clinical Research LLC-Site Number:8400010
    Shavano Park, Texas 78231-1281, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Mar 2023, 14 months.

Results were first posted in May 2024, 1 year 1 month after primary completion.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 14 months is below that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2021
First posted
Nov 10, 2021
StartActual
Jan 27, 2022
Primary completionActual
Mar 28, 2023
CompletionActual
Apr 14, 2023
Results first posted
May 24, 2024
Last update
Sep 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05114590
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Nov 10, 2021
Start date
Jan 27, 2022
Primary completion
Mar 28, 2023
Completion
Apr 14, 2023
Results posted
May 24, 2024
Last update
Sep 9, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Glargine · Lixisenatide

Start the discussion